Mounjaro injection dosage for weight loss: what the evidence shows

What the licensed dosage schedule looks like, and why it starts so low

The standard Mounjaro titration runs through six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Patients begin at 2.5 mg for the first four weeks. This is a tolerability dose, its purpose is to let your digestive system adapt to tirzepatide's mechanism (slowing gastric emptying, reducing appetite through dual GIP and GLP-1 receptor activity) before the dose climbs. Expecting meaningful weight loss during the first pen is one of the most common misconceptions people bring to their first consultation, and it is worth letting that expectation go early.

After four weeks, a prescriber will typically move the dose to 5 mg, then onward in similar four-weekly steps toward the highest dose the patient tolerates well. The NHS medicines page for tirzepatide confirms this schedule and notes that 15 mg is the maximum licensed dose. Reaching it is not mandatory, some people find an intermediate dose gives them adequate results with better tolerability, and the prescriber's job is to find that balance.

Every dose step should be guided by a clinician. Skipping steps or self-adjusting timing is not safe practice. If you are considering starting or reviewing your Mounjaro injection dosage, that conversation starts with a qualified prescriber, not an online calculator.

What the trial evidence says about dose and weight-loss outcomes

The SURMOUNT-1 trial is the foundational evidence base for Mounjaro's weight-loss dosage. Over 72 weeks, adults with obesity who received tirzepatide at 15 mg lost an average of around 20–21% of their body weight, some analyses put the figure closer to 22.5% in certain participant subgroups. Results at 10 mg and 12.5 mg were also substantial, though slightly lower on average. This dose-response relationship is why prescribers aim to reach the highest dose a patient tolerates: the evidence consistently shows more average loss at higher strengths.

That said, averages conceal real variation. Some people respond well at 7.5 mg; others need the full 15 mg and still see more modest results. The NICE appraisal of tirzepatide (Technology Appraisal TA1026) built this variability into its guidance, noting that continuing treatment at the highest tolerated dose should be reviewed if less than 5% weight loss has been achieved after six months.

These figures come from controlled clinical trials alongside reduced-calorie diet and increased physical activity. Treatment alone, without those lifestyle elements, is unlikely to replicate trial outcomes. You can read more about tirzepatide's evidence base on our Mounjaro overview page.

What affects dose progression in real-world prescribing

Dose increases in clinical practice are not automatic. A prescriber looks at how you are tolerating the current pen before recommending the next strength. Persistent nausea, vomiting or significant gastrointestinal discomfort at 5 mg, for instance, would normally prompt a longer stay at that level rather than an immediate move to 7.5 mg. Rushing titration tends to worsen side effects and can lead people to stop treatment prematurely.

At nume, every repeat order receives a fresh clinical review before dispatch. That means a GPhC-registered prescriber reads your check-in responses before authorising a dose increase, a real clinician considers your update, not an automated system. If you have questions about how titration decisions are made, our FAQs cover the most common ones, and you can always reach the team through aftercare support.

For anyone weighing up how the different strengths compare in terms of expected outcomes, our dosage and weight-loss outcomes guide goes into detail on what the data shows at each level. A closer look at the 5 mg pen specifically is useful if you are approaching your first dose increase and want to know what to expect. Private treatment prices (which vary by dose) are covered honestly on our Mounjaro prices page.

Injection technique, storage and what to do about a missed dose

Mounjaro is injected once weekly, subcutaneously, into the abdomen, thigh or upper arm. Sites should be rotated. Each KwikPen contains four doses, so one pen lasts the month. Storage is refrigerated at 2–8°C; there is a limited window during which the pen can be kept at room temperature, but for the exact duration always refer to the Patient Information Leaflet inside the pack rather than any third-party summary, that detail can vary by formulation and the leaflet is authoritative.

Missed doses and what to do about them are a question our prescribers hear regularly. The consistent clinical advice is to follow the guidance in the Patient Information Leaflet and, if in doubt, contact your prescriber. Decisions about catching up or adjusting timing should not come from a forum or a search result. If you have recently transferred to Mounjaro and want to understand how the tirzepatide injection dosage compares with other formulations, a detailed guide to tirzepatide dosage may help. Ready to discuss your suitability? Start your free consultation and a prescriber will review your answers the same day.